Privia Health Group (NASDAQ:PRVA – Get Free Report) had its price target cut by stock analysts at JPMorgan Chase & Co. from $43.00 to $38.00 in a report released on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 64.79% from the company’s current price.
Other equities analysts have also recently issued reports about the company. TD Cowen reduced their target price on Privia Health Group from $44.00 to $35.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 15th. UBS Group reduced their price objective on shares of Privia Health Group from $35.00 to $32.00 and set a “buy” rating on the stock in a research report on Friday, August 18th. Finally, Evercore ISI dropped their target price on shares of Privia Health Group from $32.00 to $26.00 in a research report on Wednesday, October 11th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $35.69.
Privia Health Group Stock Up 0.8 %
Privia Health Group (NASDAQ:PRVA – Get Free Report) last released its quarterly earnings data on Friday, November 3rd. The company reported $0.05 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.05. The firm had revenue of $417.30 million for the quarter, compared to analysts’ expectations of $410.51 million. Privia Health Group had a net margin of 2.40% and a return on equity of 6.80%. The company’s revenue for the quarter was up 21.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.01 earnings per share. As a group, equities analysts predict that Privia Health Group will post 0.21 EPS for the current fiscal year.
Insider Transactions at Privia Health Group
In other news, Director William M. Sullivan sold 18,153 shares of Privia Health Group stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $25.03, for a total value of $454,369.59. Following the completion of the transaction, the director now owns 5,510,484 shares of the company’s stock, valued at approximately $137,927,414.52. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, Director William M. Sullivan sold 18,153 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $25.03, for a total value of $454,369.59. Following the transaction, the director now directly owns 5,510,484 shares of the company’s stock, valued at approximately $137,927,414.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Thomas Bartrum sold 15,000 shares of the stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $25.77, for a total value of $386,550.00. Following the sale, the executive vice president now owns 106,114 shares in the company, valued at $2,734,557.78. The disclosure for this sale can be found here. Over the last three months, insiders have sold 51,306 shares of company stock valued at $1,321,248. Insiders own 57.60% of the company’s stock.
Hedge Funds Weigh In On Privia Health Group
Hedge funds and other institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its stake in shares of Privia Health Group by 201.7% in the 2nd quarter. BlackRock Inc. now owns 13,938,867 shares of the company’s stock worth $363,944,000 after buying an additional 9,319,052 shares during the last quarter. Durable Capital Partners LP bought a new stake in shares of Privia Health Group during the 2nd quarter valued at about $237,364,000. Vanguard Group Inc. grew its stake in shares of Privia Health Group by 7.1% during the 3rd quarter. Vanguard Group Inc. now owns 4,824,724 shares of the company’s stock valued at $164,331,000 after purchasing an additional 321,734 shares during the period. Riverbridge Partners LLC increased its position in shares of Privia Health Group by 92.3% during the 2nd quarter. Riverbridge Partners LLC now owns 4,344,042 shares of the company’s stock valued at $113,423,000 after purchasing an additional 2,084,802 shares during the last quarter. Finally, Bank of New York Mellon Corp boosted its holdings in shares of Privia Health Group by 1.6% in the third quarter. Bank of New York Mellon Corp now owns 4,040,027 shares of the company’s stock worth $92,921,000 after buying an additional 62,543 shares during the last quarter. Institutional investors own 92.40% of the company’s stock.
Privia Health Group Company Profile
Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.
- Five stocks we like better than Privia Health Group
- High Dividend REITs: Are They an Ideal Way to Diversify?
- 3 ETFs that offer extreme diversification
- Transportation Stocks Investing
- Williams-Sonoma is a steal for buy-and-hold investors
- Quiet Period Expirations Explained
- A closer look at Warren Buffett’s latest surprise purchase
Receive News & Ratings for Privia Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Privia Health Group and related companies with MarketBeat.com's FREE daily email newsletter.